Journal
VIRAL IMMUNOLOGY
Volume 23, Issue 5, Pages 477-485Publisher
MARY ANN LIEBERT INC
DOI: 10.1089/vim.2010.0034
Keywords
-
Categories
Funding
- National Institutes of Health [U19 AI057319]
- Diabetes Endocrinology Research Center (DERC), National Institute of Diabetes and Digestive and Kidney Diseases [DK32520]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI057319] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cytotoxic T lymphocytes (CTL) are hypothesized to play a role in clearance during primary dengue virus (DENV) infections, and contribute to immunopathology during secondary heterologous infections in humans. We previously reported skewed T-cell responses to secondary DENV infection in BALB/c (H-2(d)) mice, reproducing characteristics of human DENV infection. To set the stage for using widely available transgenic and knockout mice, we extended these studies to identify DENV-specific T-cell responses in C57BL/6 (H-2(b)) mice. We identified dominant CD8(+) T-cell responses to H-2D(b)-restricted epitopes on the DENV NS4a (aa 249-265) and NS5 (aa 521-537) proteins. High frequencies of IFN-gamma- and TNF-alpha-producing T cells directed at both epitopes were detected following primary infection with all four DENV serotypes, and were augmented by secondary DENV infections. In vivo cytotoxicity assays demonstrated rapid clearance of target cells pulsed with the NS4a peptide; in contrast, NS5 peptide-pulsed target cells were poorly cleared in vivo. These data characterize two H2(b)-restricted T-cell epitopes displaying divergent in vivo function. These results should facilitate further studies of the in vivo effects of DENV-specific T cells, including the use of genetically modified mouse strains.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available